The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The inspection concluded with the issuance of a form 483 with five observations
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
The net-zero target approval complements the company's near-term emission reduction targets
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Developed in consultation with clinicians and patients for an enhanced user experience
Potential of Ayurveda’s contribution in global health system through various innovative practices
Enzalutamide Capsules will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad
Subscribe To Our Newsletter & Stay Updated
